# Li Hu

Dr. Li Hu is the investment partner of Stowe Capital's China team, responsible for the management of investee companies, and works closely with the team to evaluate investment opportunities for startups in the field of new drug research and development. 30 has nearly a year of experience in small molecule and antibody drug research and development in the field of oncology and other diseases; is a co-founding team member and core executive of Shanghai Mayak Biotechnology (now a subsidiary of Lapp Biotech), worked at the GlaxoSmithKline Research and Development Center in Philadelphia, and served as a research and development biological consultant at Scinovo. Companies invested and managed include Alternative Bio, Nuclear Ark Medicine, Ray Medicine, and others.

Dr. Li Hu is the investment partner of Stowe Capital's China team, responsible for the management of investee companies, and works closely with the team to evaluate investment opportunities for startups in the field of new drug research and development. 30 has nearly a year of experience in small molecule and antibody drug research and development in the field of oncology and other diseases; is a co-founding team member and core executive of Shanghai Mayak Biotechnology (now a subsidiary of Lapp Biotech), worked at the GlaxoSmithKline Research and Development Center in Philadelphia, and served as a research and development biological consultant at Scinovo. Companies invested and managed include Alternative Bio, Nuclear Ark Medicine, Ray Medicine, and others.

Canonical: https://uniquebase.ai/people/li-hu
Stable identifier: UB-P4106
Snapshot captured: 2026-10-22T00:48:04.883Z
English updated: 2026-10-22T00:59:15.772Z

## Sources

- No source links are available for this profile.